This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pfizer, BioNTech objection to CureVac's new arguments referred to US magistrate

By Melissa Ritti ( November 12, 2024, 21:15 GMT | Insight) -- The addition of eight new secondary considerations of nonobviousness by patent owner CureVac two months after the close of fact discovery and five months before trial is “procedural chicanery,” infringement defendants Pfizer and BioNTech say.  A US judge today referred their motion to strike a CureVac expert report to a federal magistrate for disposition.CureVac misled as to the scope of its secondary considerations of nonobviousness for two patents just long enough to nudge Pfizer and BioNTech into dropping a related motion to compel, according to the defendants, makers of the Comirnaty Covid-19 vaccine....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections